Do we really need a $443 million smallpox drug?

Summary:Siga Technologies was awarded a U.S. government contract worth $433 million to develop an experimental drug for smallpox. The problem: it was eradicated in 1978.

An alarming report in the Los Angeles Times this month notes that New York-based pharmaceutical company Siga Technologies was awarded a U.S. government contract worth $433 million to develop an experimental smallpox drug.

The problem: smallpox was eradicated across the globe by 1978. It exists "only in the locked freezers of a Russian scientific institute and the U.S. government," David Willman writes.

The contract calls for the company to deliver 1.7 million doses of the drug -- at $225 per dose -- for the United States' biodefense stockpile. (Theoretically, a terrorist could cause harm with smallpox; on the other hand, no credible evidence exists that anyone has the stuff.)

Currently, the U.S. government has more than $1 billion worth of smallpox vaccine on hand -- at $3 per dose -- in case the threat ever goes viral again. (Pun very much intended.) Williams' report suggests that the contract was more the product of political glad-handing than actual problem-solving.

There is a difference between the treatments. The government's existing vaccine can prevent death in those who receive it within four days of infection; Siga's antiviral ST-246 pill treats those who miss that four-day window.

One hiccup: the drug can't be tested in humans because it would be unethical to infect someone with the pathogen for the sake of scientific research.

Do we really need a new drug for smallpox? Is research without an immediate application worth pursuing?

This post was originally published on

Topics: Innovation


Andrew Nusca is a former writer-editor for ZDNet and contributor to CNET. He is also the former editor of SmartPlanet, ZDNet's sister site about innovation. He writes about business, technology and design now but used to cover finance, fashion and culture. He was an intern at Money, Men's Vogue, Popular Mechanics and the New York Daily Ne... Full Bio

zdnet_core.socialButton.googleLabel Contact Disclosure

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Related Stories

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.